keyboard_arrow_up

TNF Antibodies - Biosimilars and Biosuperiors

Reportstack has announced a new market research publication on TNF Antibodies - Biosimilars and Biosuperiors which provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The therapeutic drug class of TNF antibodies presently consists of five different approved and marketed products which all together achieved worldwide sales of US$ 30.5 bln in 2013. Among the approved indications for use of TNF antibodies in general are rheumatoid arthritis, idiopathic juvenile arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, psoriasis, ulcerative colitis and Crohn’s disease. However, not all TNF antibodies are the same and their efficacy had to be demonstrated for each indication.

The highly attractive market and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. For all of the five marketed TNF antibodies are biosimilar molecules in the R&D pipeline, but with clear priority on the first generation TNF antibody constructs.

The report includes a compilation of currently active projects in development of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

To view the table of contents and know more details please visit TNF Antibodies - Biosimilars and Biosuperiors report.